Drug-induced iatrogenic hallucinations and psychosis occur in about 30% of Parkinson's disease (PD) patients and are the single most important precipitant for nursing home placement, which carries a grave prognosis. In addition, parkinsonism is a frequent accompaniment to the more common dementing syndromes, Alzheimer's disease (AD), vascular dementia, and dementia with Lewy bodies (DLB). The five most recent antipsychotic drugs approved by the Food and Drug Administration in the United States have been marketed as “atypical” antipsychotics (AA) due to their relative freedom from extrapyramidal symptoms when used in schizophrenia patients. The use of these newer antipsychotic drugs in PD and other parkinson-sensitive populations represents the most stringent test to their freedom from motor side effects. To date, clozapine, risperidone, olanzapine, and quetiapine have been studied in parkinson-vulnerable populations. This article reviews the data and highlights the differences that these four drugs have on motor function. It also emphasizes the challenges in evaluating the available data on the motor effects of AA, especially on the non-PD elderly and cognitively impaired population. Suggestions are made for future research to improve the interpretability of these studies.
Get full access to this article
View all access options for this article.
References
1.
1. Freyhan FA., Comments on the biological and psychopathological basis of individual variation in chlorpromazine therapy. Encephale1957; 45: 913–919.
3. Baldessarini RJ., Drugs and the treatment of psychiatric disorders: psychosis and anxiety. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds., Goodman & Gilman's the pharmacological basis of therapeutics. 9th Ed.New York: McGraw-Hill, 1995: 399–430.
4.
4. Haase HJ., Extrapyramidal modification of fine movements: a “conditio sine qua non” of the fundamental therapeutic action of neuroleptic drugs. Rev Can Biol1961; 20: 425–449.
5.
5. Patterns of dystonia (“I-D-I” and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. Mayo Clin Proc1977; 52: 163–174.
7. Fenelon G, Mahieux F, Huon R, Ziegler M., Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain2000; 123: 733–745.
8.
8. Factor SA, Molho ES, Podskalny GD, Brown D., Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE, eds., Behavioral neurology of movement disorders. Advances in neurology. Vol. 65. New York: Raven Press, 1995: 115–138.
9.
9. Celesia GC, Barr AN., Psychosis and psychiatric manifestations of levodopa therapy. Arch Neurol1970; 23: 193–200.
10.
10. Cotzias GC, Papavasilou PS, Ginos JZ, et al., Metabolic modification of Parkinson's disease and of chronic manganese poisoning. Annu Rev Med1971; 22: 205–326.
11.
11. Goodwin FK., Psychiatric side effects of levodopa in men. JAMA1971; 218: 1915–1921.
12.
12. Jenkins RB, Groh RH., Mental symptoms in parkinsonian patients treated with L-dopa. Lancet1970; 2: 177–180.
14. Dewey RB, O'Suilleabhain PE., Treatment of drug induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology2000; 55: 1753–1754.
15.
15. Aarsland D, Larsen JP, Cummings JL, Laake K., Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community based study. Arch Neurol1999; 56: 595–601.
16.
16. Goetz CG, Stebbins GT., Risk factors for nursing home placement in advanced Parkinson's disease. Neurology1993; 43: 2227–2229.
17.
17. Aarsland D, Larsen JP, Tandberg E, Laake K., Predictors of nursing home placement in Parkinson's disease: a population based prospective study. J Am Geriatr Soc2000; 48: 938–942.
18.
18. Liu K, Manton KG., The characteristics and utilization pattern of an admission cohort of nursing home patients. Gerontologist1983; 23: 92–98.
19.
19. Goldman SM, Tanner C., Etiology of Parkinson's disease. In: Jankovic J, Tolosa E, eds., Parkinson's disease & movement disorders. 3rd Ed.Baltimore: Williams & Wilkins, 1998: 133–158.
20.
20. Moskowitz C, Moses H III, Klawans HL., Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry1978; 135: 669–675.
21.
21. Scholz E, Dichgans J., Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci1985; 235: 60–64.
22.
22. Friedman JH, Max J, Swift R., Idiopathic Parkinson's disease in a chronic schizophrenic patient. Long-term treatment with clozapine and L-dopa. Clin Neuropharmacol1987; 10: 470–475.
23.
23. Bear D, Lawson W, Burns S, et al., Clozapine in idiopathic Parkinson's. Biol Psychiatry1989; 25: 160A–165A.
24.
24. Bernardi F, Del Zompa M., Clozapine in idiopathic Parkinson's disease [letter]. Neurology1990; 40: 1151.
25.
25. Brewer MA, Kurth MC, Imke SC, Lieberman AN., Safety and effectiveness of clozapine for parkinsonian patients with psychosis. Neurology1995; 45(Suppl 4): A252.
26.
26. Chacko RC, Hurley RA, Harper RG, et al., Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci1995; 7: 471–475.
27.
27. Diederich N, Keipes M, Graas M, Metz H., Clozapine in the treatment of mental manifestations of Parkinson's disease. Rev Neurol (Paris) 1995; 151: 251–257.
28.
28. Factor SA, Brown D, Molho ES, Podskalny GD., Clozapine: a two-year open trial in Parkinson's disease patients with psychosis. Neurology1994; 44: 544–546.
29.
29. Factor SA, Brown D., Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord1992; 7: 125–131.
30.
30. Friedman JH, Lannon MC, Caley C., Clozapine for movement disorder patients: a retrospective analysis of 38 patients. Ann Neurol1992; 32: 277.
31.
31. Gonski PN., The use of clozapine in Parkinson's disease. Aust N Z J Med1994; 24: 585.
32.
32. Greene P, Cote L, Fahn S., Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol1993; 60: 703–706.
33.
33. Kahn N, Freeman A, Juncos JL, et al., Clozapine is beneficial for psychosis in Parkinson's disease. Mov Disord1992; 41: 1699–1700.
34.
34. Lanazasoro G, Suarez JA, Marti Masso JF., Clozapine in Parkinson's disease: three years experience. Mov Disord1992; 7(Suppl): 100.
35.
35. Lew MF, Waters CF., Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc1993; 41: 669–671.
36.
36. Ostergaard K, Dupont E., Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurol Scand1988; 78: 349–350.
37.
37. Pfeiffer RF, Kang J, Graber B, et al., Clozapine for psychosis in Parkinson's disease. Mov Disord1990; 5: 239–242.
38.
38. Pinter MM, Helscher RJ., Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm1993; 5: 135–146.
39.
39. Rabey JM, Treves TA, Neufeld MY, et al., Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology1995; 45: 432–434.
40.
40. Roberts HE, Dean RC, Stoudemire A., Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry1989; 1: 190–192.
41.
41. Rosenthal SH, Fenton ML, Harnett DS., Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease. Gen Hosp Psychiatry1992; 14: 285–286.
42.
42. Ruggieri S, De Pandis MF, Bonamartini A, et al., Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol1997; 20: 204–209.
43.
43. Rui-Silva M, Magalhaes M, Viseu M, Bastos Lima A., Clozapine in the treatment of psychosis in parkinsonism. J Neurol1995; 242(Suppl 2): 138.
44.
44. Trosch RM, Friedman JH, Lannon MC, et al., Clozapine use in Parkinson's disease. A retrospective analysis of a large multi-centered clinical experience. Mov Disord1998; 13: 377–382.
45.
45. Wagner ML, Defilippi JL, Menza MM, Sage JI., Clozapine for the treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci1996; 8: 276–280.
46.
46. Wolk SI, Douglas CJ., Clozapine treatment of psychosis in Parkinson's disease: a report of 5 consecutive cases. J Clin Psychiatry1992; 53: 373–376.
47.
47. Wolters ECH, Hurwitz TA, Mak E, et al., Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology1990; 40: 832–834.
48.
48. Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med1999; 340: 757–763.
49.
49. The French Clozapine Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet1999; 353: 2041–2042.
50.
50. Mohr E, Mendis TF, Hildebrand K, DeDeyn PP., Risperidone in the treatment of dopamine induced psychosis is Parkinson's disease: an open pilot trial. Mov Disord2000; 15: 1230–1237.
51.
51. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmens PL., Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology1996; 47: 1085–1087.
52.
52. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M., Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord1999; 14: 484–487.
53.
53. D'Souza S, Barnett SK, Rangu S, Rowland FN., Treatment of psychosis in Parkinson's disease. J Am Med Dir Assoc2000; 1: 211–216.
54.
54. Richard IH, Nutt J., Worsening of motor function in Parkinson's disease: a “typical” response to “atypical” antipsychotic medications. Neurology2000; 55: 748.
55.
55. Standaert DG, Young AB., Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds., Goodman & Gilman's the pharmacological basis of therapeutics. 9th Ed.New York: McGraw-Hill, 1995: 503–520.
56.
56. Meltzer HY, Matsubara S, Lee JC., Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2 and serotonin 2 pK values. J Pharmacol Exp Ther1989; 251: 238–246.
57.
57. Baldessarini RJ, Frankenburg FR., Clozapine: a novel antipsychotic agent. N Engl J Med1991; 324: 746–754.
58.
58. Friedman JH., Young onset Parkinson's disease in a patient with schizophrenia; autopsy confirmation. Clin Neuropharmacol (in press).
59.
59. Factor SA, Friedman JH., The emerging role of clozapine in the treatment of movement disorders. Mov Disord1997; 12: 483–496.
60.
60. Pakkenberg H, Pakkenberg B., Clozapine in the treatment of tremor. Acta Neurol Scand1986; 73: 295–297.
61.
61. Fischer PA, Baas H, Hefner R., Treatment of parkinsonian tremor with clozapine. J Neural Transm1990; 2: 233–238.
63. Friedman JH, Lannon MC., Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology1997; 4: 1077–1081.
64.
64. Jansen ENH., Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand1994; 89: 262–265.
65.
65. Bonuccelli U, Ceravolo R, Salvetti S, et al., Clozapine in Parkinson's disease tremor: effects of acute and chronic administration. Neurology1997; 49: 1587–1590.
66.
66. Friedman JH, Factor SA., Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord2000; 151: 201–211.
67.
67. Alvir JMA, Lieberman JA, Safferman AZ., Clozapine induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med1993; 329: 162–167.
68.
68. Honigfeld G, Arellano F, Sethi J, et al., Reducing clozapine-related morbidity and mortality: 5 years of experience with clozapine national registry. J Clin Psychiatry1998; 59(Suppl 3), 3–7.
77. Arndt J, Skarsfeld T., Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology1998; 18: 63–101.
78.
78. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH., Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry J Clin Neurosci2000; 12: 364–369.
79.
79. Meco G, Alessandri A, Bonifati V, Guistini P., Risperidone for hallucinations in levodopa treated Parkinson's disease patients. Lancet1994; 343: 1370–1371.
80.
80. Ford B, Lynch T, Greene P., Risperidone in Parkinson's disease. Lancet1994; 344: 681.
81.
81. Rich SS, Friedman JH, Ott BR., Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry1995; 56: 556–559.
82.
82. Workman RJ Jr, Orengo CA, Bakey AA, et al., The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci1997; 9: 594–597.
83.
83. Meco G, Alessandri A, Guistini P, Bonifati V., Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open label long term study. Mov Disord1997; 12: 610–612.
84.
84. Leopold NA., Risperidone treatment of drug related psychosis in patients with parkinsonism. Mov Disord2000; 15: 301–304.
85.
85. Factor SA, Molho ES, Friedman JH., Risperidone in the treatment of dopamine induced psychosis in Parkinson's disease. Mov Disord (in press).
86.
86. Rosebush PI, Mazurek MF., Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology1999; 52: 782–785.
87.
87. David SR, Taylor CC, Kinon BJ, Breier A., The effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther2000; 22: 1085–1096.
88.
88. Moore NA, Tye NC, Axton MS, et al., The behavioral pharmacology of olanzapine a novel atypical antipsychotic agent. J Pharmacol Exp Ther1992; 262: 545–551.
89.
89. Moore NA, Coligaro DO, Wong DT, et al., The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drug1993; 2: 281–293.
90.
90. Jimenez-Jimenez FJ, Talon-Barranco A, Orti-Pareja, et al., Olanzapine can worsen parkinsonism. Neurology1998; 50: 1183–1184.
91.
91. Friedman JH, Goldstein SM., Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology1998; 50: 1195–1196.
92.
92. Friedman JH, Goldstein SM, Jacques C., Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open-label pilot trial. Clin Neuropharmacol (in press).
93.
93. Molho ES, Factor SA., Worsening of motor features of Parkinson's disease with olanzapine. Mov Disord1999; 14: 1014–1016.
94.
94. Churchyard A, Iansek R., Olanzapine as treatment of the neuropsychiatric complications of Parkinson's disease: an open-label study. Mov Disord1998; 13(Suppl 2): 188.
95.
95. Weiner WJ, Minagar A, Shulman L., Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease. Mov Disord1998; 13(Suppl 2): 62.
96.
96. Graham JM, Sussman JP, Ford KS, Sagar HJ., Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry1998; 65: 774–777.
97.
97. Stover NP, Juncos JL., Olanzapine treatment of parkinsonian patients with psychosis. Neurology1999; 52(Suppl 2): A215.
98.
98. Aarsland D, Larsen J, Lim NG, Tandberg E., Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci1999; 11: 392–394.
99.
99. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ., Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology2000; 55: 789–794.
100.
100. Gimenez-Roldan S, Mateo D, Navarro E, Gines MM., Efficacy and safety of clozapine and olanzapine: an open label trial comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord2001; 7: 121–127.
101.
101. Manson AJ, Schrag A, Lees AJ., Low-dose olanzapine for levodopa induced dyskinesias. Neurology2000; 55: 795–799.
102.
102. Rudolf J, Ghaemi M, Schmulling S., Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. Eur Psychiatr1999; 14: 356–357.
103.
103. Evatt ML, Lewart D, Juncos JL., “Seroquel” treatment of psychosis in parkinsonism. Mov Disord1996; 11: 595.
104.
104. Parsa MA, Bastani B., Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci1998; 10: 216–219.
105.
105. Juncos JL, Evatt ML, Jewart D., Long term effect of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology1998; 50: 70–71.
107. Samanta J, Stacy M., Quetiapine in the treatment of hallucinations in advanced Parkinson's disease. Mov Disord1998; 13(Suppl 2): 274.
108.
108. Fernandez HH, Lannon MC, Friedman JH, Abbot BP., Clozapine replacement by quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord2000; 15: 579–581.
109.
109. Targum SD, Abbott JL.Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol2000; 20: 54–60.
110.
110. Factor SA, Reddy S, Molho ES, Feustel PJ., The effect of quetiapine on psychosis and motor function in Parkinsonian patients with and without dementia. Mov Disord2000; 15: 1040.
111.
111. Fernandez HH, Friedman JH, Jacques C, et al., Quetiapine in the treatment of drug induced psychosis in Parkinson's disease. Movement Awards2001; 16(Suppl 1): 32.
112.
112. Menza MM, Palermo B, Mark M., Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry1999; 11: 141–144.
113.
113. Weiner WJ, Winagar A, Shulman LM., Quetiapine for L-dopa induced psychosis in PD. Neurology2000; 54: 1538.
114.
114. Fernandez HH., Quetiapine for L-dopa-induced psychosis in PD. Neurology2000; 55: 899.
115.
115. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M., Quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord1999; 14: 484–487.
116.
116. Fernandez HH, Trieschmann ME, Burke MA, et al., Drug-induced psychosis in Parkinsonian syndromes: predictors of quetiapine non-response. Presented at the 15th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Chicago, IL, September 30, 2001.
117.
117. Funkenstein HH, Albert MS, Cook NR, et al., Extrapyramidal signs and other neurologic findings of clinically diagnosed Alzheimer's disease. A community-based study. Arch Neurol1993; 50: 51–56.
118.
118. Molsa PK, Martilla RS, Rinne UK., Extrapyramidal signs in Alzheimer's disease. Neurology1984; 34: 1114–1116.
119.
119. Liu Y, Stern Y, Chun MR, et al., Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol1997; 41: 368–374.
120.
120. DeReuck J, Siau B, DeCoo D, et al., Parkinsonism in patients with vascular dementia: clinical, computed and positron emission tomographic findings. Cerebrovasc Dis2001; 11: 51–58.
121.
121. Elble RJ, Cousins R, Leffler K, Hughes L., Gait initiation by patients with lower half parkinsonism. Brain1996; 119: 1705–1716.
122.
122. McKeith IG, Perry EK, Perry RH., Report of the Second Dementia with Lewy Body International Workshop. Neurology1999; 53: 902–905.
123.
123. Litvan I, MacIntyre A, Goetz CG, et al., Accuracy of the clinical diagnoses of Lewy body disease, Parkinson's disease and dementia with Lewy bodies. Arch Neurol1998; 55: 969–978.
124.
124. Ma J, Alvir J, Lieberman JA, et al., Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med1993; 329: 162–167.
125.
125. Oberholzer AF, Hendriksen D, Monsch AK, et al., Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr1992; 4: 187–195.
126.
126. Frankenburg FR, Kalunian, A retrospective study on eight patients ages 68–80. Clozapine in the elderly. J Geriatr Psychiatry Neurol1994; 7: 129–132.
127.
127. Chengappa KNR, Maker RW, Kreinbrook SB, et al., Clozapine use in female geriatric patient with psychoses. J Geriatr Psychiatry Neurol1995; 8: 12–15.
128.
128. Pitner JK, Mintzer JE, Pennypacker LC, et al., Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry1995; 56: 180–185.
129.
129. Saltzman C, Vaccaro B, Lieff J, et al., Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry1995; 3: 26–33.
130.
130. Ayd FJ Jr., Risperidone: a unique antipsychotic. Int Drug Ther Newsl1994; 29: 5–12.
131.
131. Raheja RJ, Bharwani I, Penetrante AE., Efficacy of risperidone for behavioral disorders in the elderly. J Geriatr Psychiatry Neurol1995; 8: 159–161.
132.
132. Madhusoodanan S, Brenner R, Araujo L, Abaza A., Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry1995; 56: 514–518.
133.
133. Madhusoodanan S, Suresh P, Brenner R, Pillai R., Experience with the atypical antipsychotics—risperidone and olanzapine in the elderly. Ann Clin Psychiatry1999; 11: 113–118.
134.
134. Zarate CA, Baldessarini RJ, Siegal AJ, et al., Risperidone in the elderly: a pharmacoepidemiological study. J Clin Psychiatry1987; 58: 311–331.
135.
135. Katz IR, Jeste DV, Mintzer JE, et al., Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. J Clin Psychiatry1999; 60: 107–115.
136.
136. Goldberg RJ, Goldberg J., Risperidone for dementia related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatrics1997; 9: 65–68.
137.
137. Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al., Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci1999; 11: 336–342.
138.
138. Dedeyn PP, Rabberu K, Rasmussen A, et al., A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology1999; 53: 946–955.
139.
139. Frenchman IB, Prince T., Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr1997; 9: 431–435.
140.
140. Lavretsky H, Sultzer D., A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry1998; 6: 127–135.
141.
141. Jeste DV, Eastham JH, Lacro JP, et al., Management of latelife psychosis. J Clin Psychiatry1996; 57(Suppl 3), 39–45.
142.
142. Hermann N, Rivard MF, Flynn M, et al., Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci1998; 10: 22–23.
143.
143. Sajatovic M, Ramirez LF, Vernon L, et al., Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry1996; 26: 309–317.
144.
144. Kopala LC, Honer WG., The use of risperidone in severely demented patients with persistent vocalizations. Int J Geriatr Psychiatry1997; 2: 73–77.
145.
145. JeanBlanc W, Davis YB., Risperidone for treating dementia-associated aggression. Am J Psychiatry1995; 152: 1239.
146.
146. Kiraly SG, Gibson RE, Ancill RJ., Risperidone: treatment response in adult and geriatric patients. Int J Psychiatry Med1998; 28: 255–263.
147.
147. Rosebush PI, Mazurek MF., Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology1999; 52: 782–785.
148.
148. Magnuson TM, Roccaforte WH, Wengel SP, Burke WJ., Medication-induced dystonias in nine patients with dementia. J Neuropsychiatry Clin Neurosci2000; 12: 219–225.
149.
149. Solomons K, Geiger O., Olanzapine use in the elderly: a retrospective analysis. Can J Psychiatry2000; 45: 151–155.
150.
150. Madhusoodanan S, Brenner R, Suresh P, et al., Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry2000; 12: 11–18.
151.
151. Gaile S, Noviasky JA., Speech disturbance and marked decrease in function seen in several older patients on olanzapine. J Am Geriatr Soc1998; 46: 1330–1331.
152.
152. Street JS, Clark WS, Cumming JL, et al., Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double blind, placebo controlled trial. The HGEU Study Group. Arch Gen Psychiatry2000; 57: 968–976.
153.
153. Sajatovic M, Perez D, Drescan D, Ramirez LF., Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol Bull1998; 34: 819–823.
154.
154. McManus DQ, Arvantis LA, Kowalcyk B, et al., Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry1999; 60: 292–298.
155.
155. Tariot PN, Salzman C, Yeung PP, et al., Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther2000; 22: 1068–1084.
156.
156. Madhusoodanan S, Brenner R, Alcantra A., Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol2000; 13: 28–31.
157.
157. Holmes L, Cairns N, Lantos P, Mann A., Validity of clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry1999; 174: 45.
158.
158. Allen RL, Walker Z, D'Ath PJ, Katona CL., Risperidone for psychotic and behavioral symptoms in Lewy body dementia. Lancet1995; 346: 185.
159.
159. McKeith IF, Ballard CG, Harrison RW., Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet1995; 346: 699.
160.
160. Sechi G, Agnetti V, Masuri R, et al., Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry2000; 24: 1043–1051.
161.
161. Walker Z, Grace J, Overshot R, et al., Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry1999; 14: 459–466.
162.
162. Fernandez HH, Trieshmann ME, Burke MA, et al., Long-term outcome of quetiapine use for psychosis: Parkinson's disease versus dementia with Lewy bodies. Mov Disord2001; 16(Suppl 1): 32.
163.
163. Friedman JH., Drug induced parkinsonism. In: Lang AE, ed., Drug induced movement disorders. Mt. Kisco: Futura Publishing Co., Inc.. 1992; 41–84.
164.
164. Richelson E., Receptor pharmacology of neuroleptics. Relation to clinical effects. J Clin Psychiatry1999; 60(Suppl 10), 5–14.
165.
165. Kinon BJ, Lieberman JA., Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology1996; 124: 2–31.
166.
166. Casey DE., The relationship of pharmacology to side effects. J Clin Psychiatry1997; 58: 55–62.
167.
167. Hansen TE, Brown WL, Weigel RM, Casey DE., Under-recognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry1992; 14: 340–344.
168.
168. Weiden PJ, Mann JJ, Haas G., Clinical non-recognition of drug induced movement disorders: a cautionary study. Am J Psychiatry1987; 144: 1148–1153.
169.
169. Rifkin A, Quitkin F, Klein DF., Akinesia: a poorly recognized drug induced extrapyramidal behavior disorder. Arch Gen Psychiatry1975; 32: 672–674.
170.
170. Stephen PJ, Williamson J., Drug-induced parkinsonism in the elderly. Lancet1984; 11: 1082–1083.
171.
171. Lapane KL, Fernandez HH, Friedman JH, et al., Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term facilities. SAGE Study Group. Pharmacotherapy1999; 19: 1321–1327.
